GH Research (GHRS) Competitors

$21.88 +0.34 (+1.58%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$22.02 +0.15 (+0.66%)

As of 05/13/2026 07:30 PM Eastern

GHRS vs. APLS, APGE, DNTH, CRSP, and INDV

Should you buy GH Research stock or one of its competitors? MarketBeat compares GH Research with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GH Research include Apellis Pharmaceuticals (APLS), Apogee Therapeutics (APGE), Dianthus Therapeutics (DNTH), CRISPR Therapeutics (CRSP), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry.

How does GH Research compare to Apellis Pharmaceuticals?

Apellis Pharmaceuticals (NASDAQ:APLS) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

In the previous week, Apellis Pharmaceuticals had 3 more articles in the media than GH Research. MarketBeat recorded 4 mentions for Apellis Pharmaceuticals and 1 mentions for GH Research. Apellis Pharmaceuticals' average media sentiment score of 1.45 beat GH Research's score of 0.97 indicating that Apellis Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Apellis Pharmaceuticals	Positive
GH Research	Positive

Apellis Pharmaceuticals has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apellis Pharmaceuticals	$1.00B	5.23	$22.39M	$1.02	40.23
GH Research	N/A	N/A	-$48.26M	-$0.80	N/A

Apellis Pharmaceuticals has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market. Comparatively, GH Research has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

96.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by company insiders. Comparatively, 41.6% of GH Research shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Apellis Pharmaceuticals currently has a consensus price target of $35.72, suggesting a potential downside of 12.94%. GH Research has a consensus price target of $40.13, suggesting a potential upside of 83.39%. Given GH Research's stronger consensus rating and higher probable upside, analysts clearly believe GH Research is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Apellis Pharmaceuticals has a net margin of 12.06% compared to GH Research's net margin of 0.00%. Apellis Pharmaceuticals' return on equity of 39.71% beat GH Research's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apellis Pharmaceuticals	12.06%	39.71%	13.20%
GH Research	N/A	-16.30%	-15.77%

Summary

Apellis Pharmaceuticals beats GH Research on 10 of the 15 factors compared between the two stocks.

How does GH Research compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

GH Research's return on equity of -16.30% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
GH Research	N/A	-16.30%	-15.77%

Apogee Therapeutics currently has a consensus price target of $112.73, indicating a potential upside of 34.30%. GH Research has a consensus price target of $40.13, indicating a potential upside of 83.39%. Given GH Research's higher possible upside, analysts plainly believe GH Research is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Comparatively, 41.6% of GH Research shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GH Research is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.22	N/A
GH Research	N/A	N/A	-$48.26M	-$0.80	N/A

In the previous week, Apogee Therapeutics had 10 more articles in the media than GH Research. MarketBeat recorded 11 mentions for Apogee Therapeutics and 1 mentions for GH Research. GH Research's average media sentiment score of 0.97 beat Apogee Therapeutics' score of 0.91 indicating that GH Research is being referred to more favorably in the news media.

Company	Overall Sentiment
Apogee Therapeutics	Positive
GH Research	Positive

Apogee Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, GH Research has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Summary

GH Research beats Apogee Therapeutics on 8 of the 14 factors compared between the two stocks.

How does GH Research compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Dianthus Therapeutics presently has a consensus target price of $117.82, indicating a potential upside of 37.41%. GH Research has a consensus target price of $40.13, indicating a potential upside of 83.39%. Given GH Research's higher probable upside, analysts clearly believe GH Research is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

GH Research has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. GH Research's return on equity of -16.30% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
GH Research	N/A	-16.30%	-15.77%

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 41.6% of GH Research shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Dianthus Therapeutics had 15 more articles in the media than GH Research. MarketBeat recorded 16 mentions for Dianthus Therapeutics and 1 mentions for GH Research. Dianthus Therapeutics' average media sentiment score of 1.17 beat GH Research's score of 0.97 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Dianthus Therapeutics	Positive
GH Research	Positive

Dianthus Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, GH Research has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

GH Research has lower revenue, but higher earnings than Dianthus Therapeutics. GH Research is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,297.75	-$162.34M	-$4.13	N/A
GH Research	N/A	N/A	-$48.26M	-$0.80	N/A

Summary

GH Research beats Dianthus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does GH Research compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and GH Research (NASDAQ:GHRS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

GH Research has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. GH Research's return on equity of -16.30% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
GH Research	N/A	-16.30%	-15.77%

CRISPR Therapeutics currently has a consensus price target of $65.47, suggesting a potential upside of 24.11%. GH Research has a consensus price target of $40.13, suggesting a potential upside of 83.39%. Given GH Research's stronger consensus rating and higher probable upside, analysts clearly believe GH Research is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, CRISPR Therapeutics had 26 more articles in the media than GH Research. MarketBeat recorded 27 mentions for CRISPR Therapeutics and 1 mentions for GH Research. GH Research's average media sentiment score of 0.97 beat CRISPR Therapeutics' score of 0.70 indicating that GH Research is being referred to more favorably in the news media.

Company	Overall Sentiment
CRISPR Therapeutics	Positive
GH Research	Positive

GH Research has lower revenue, but higher earnings than CRISPR Therapeutics. GH Research is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,449.50	-$581.60M	-$6.22	N/A
GH Research	N/A	N/A	-$48.26M	-$0.80	N/A

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 56.9% of GH Research shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 41.6% of GH Research shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, GH Research has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

Summary

GH Research beats CRISPR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does GH Research compare to Indivior?

GH Research (NASDAQ:GHRS) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Indivior has a net margin of 19.44% compared to GH Research's net margin of 0.00%. GH Research's return on equity of -16.30% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-16.30%	-15.77%
Indivior	19.44%	-219.26%	29.40%

GH Research currently has a consensus price target of $40.13, suggesting a potential upside of 83.39%. Indivior has a consensus price target of $39.33, suggesting a potential upside of 2.56%. Given GH Research's higher probable upside, equities research analysts plainly believe GH Research is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Indivior had 5 more articles in the media than GH Research. MarketBeat recorded 6 mentions for Indivior and 1 mentions for GH Research. Indivior's average media sentiment score of 1.37 beat GH Research's score of 0.97 indicating that Indivior is being referred to more favorably in the news media.

Company	Overall Sentiment
GH Research	Positive
Indivior	Positive

Indivior has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.80	N/A
Indivior	$1.24B	3.77	$210M	$1.95	19.67

56.9% of GH Research shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 41.6% of GH Research shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

GH Research has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Indivior has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Summary

Indivior beats GH Research on 11 of the 16 factors compared between the two stocks.

Get GH Research News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GHRS vs. The Competition

Export

Metric	GH Research	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.34B	$3.42B	$6.30B	$12.20B
Dividend Yield	N/A	2.29%	2.79%	5.30%
P/E Ratio	-27.35	18.52	21.23	25.65
Price / Sales	N/A	301.26	558.10	79.80
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	4.85	6.75	9.70	6.66
Net Income	-$48.26M	$24.11M	$3.55B	$333.63M
7 Day Performance	4.14%	-0.53%	-0.55%	-0.11%
1 Month Performance	30.47%	0.34%	1.19%	3.94%
1 Year Performance	119.24%	78.62%	41.20%	36.07%

GH Research Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GHRS GH Research	3.5102 of 5 stars	$21.88 +1.6%	$40.13 +83.4%	+117.5%	$1.34B	N/A	N/A	10
APLS Apellis Pharmaceuticals	2.2497 of 5 stars	$40.95 -0.1%	$34.89 -14.8%	+137.4%	$5.24B	$1.00B	314.99	770	Positive News Earnings Report
APGE Apogee Therapeutics	2.9575 of 5 stars	$83.48 -0.1%	$112.73 +35.0%	+111.2%	$5.16B	N/A	N/A	91	Earnings Report
DNTH Dianthus Therapeutics	3.0784 of 5 stars	$89.79 +0.5%	$115.55 +28.7%	+355.1%	$4.89B	$2.04M	N/A	80	Positive News
CRSP CRISPR Therapeutics	3.1366 of 5 stars	$50.33 -6.1%	$64.53 +28.2%	+41.7%	$4.85B	N/A	N/A	460	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GHRS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GH Research (GHRS) Competitors

GHRS vs. APLS, APGE, DNTH, CRSP, and INDV

How does GH Research compare to Apellis Pharmaceuticals?

Summary

How does GH Research compare to Apogee Therapeutics?

Summary

How does GH Research compare to Dianthus Therapeutics?

Summary

How does GH Research compare to CRISPR Therapeutics?

Summary

How does GH Research compare to Indivior?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GH Research (GHRS) Competitors

GHRS vs. APLS, APGE, DNTH, CRSP, and INDV

How does GH Research compare to Apellis Pharmaceuticals?

Does the media refer more to APLS or GHRS?

Which has better valuation and earnings, APLS or GHRS?

Which has more risk & volatility, APLS or GHRS?

Do institutionals & insiders hold more shares of APLS or GHRS?

Do analysts recommend APLS or GHRS?

Is APLS or GHRS more profitable?

Summary

How does GH Research compare to Apogee Therapeutics?

Is APGE or GHRS more profitable?

Do analysts recommend APGE or GHRS?

Do insiders and institutionals hold more shares of APGE or GHRS?

Which has preferable valuation & earnings, APGE or GHRS?

Does the media prefer APGE or GHRS?

Which has more risk and volatility, APGE or GHRS?

Summary

How does GH Research compare to Dianthus Therapeutics?

Do analysts recommend DNTH or GHRS?

Is DNTH or GHRS more profitable?

Do insiders & institutionals hold more shares of DNTH or GHRS?

Does the media prefer DNTH or GHRS?

Which has more risk & volatility, DNTH or GHRS?

Which has stronger earnings and valuation, DNTH or GHRS?

Summary

How does GH Research compare to CRISPR Therapeutics?

Is CRSP or GHRS more profitable?

Do analysts rate CRSP or GHRS?

Does the media prefer CRSP or GHRS?

Which has stronger valuation & earnings, CRSP or GHRS?

Do institutionals and insiders hold more shares of CRSP or GHRS?

Which has more volatility and risk, CRSP or GHRS?

Summary

How does GH Research compare to Indivior?

Is GHRS or INDV more profitable?

Do analysts rate GHRS or INDV?

Does the media favor GHRS or INDV?

Which has preferable valuation & earnings, GHRS or INDV?

Do insiders and institutionals have more ownership in GHRS or INDV?

Which has more risk & volatility, GHRS or INDV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS vs. The Competition

GH Research Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools